Abstract
Bipolar affective disorder (BD) is a severe, recurrent and disabling disorder with devastating consequences for individuals, families and society. Although these hazards and costs provide a compelling rationale for development of early detection and early intervention strategies in BD, the development of at-risk criteria for first episode mania is still in an early stage of development. In this paper we review the literature with respect to the clinical, neuroantomical and neuropsychological data, which support this goal. We also describe our recently developed bipolar at-risk criteria (BAR). This criteria comprises the peak age range of the first onset of bipolar disorder, genetic risk, presenting with sub-threshold mania, cyclothymic features or depressive symptoms. An initial pilot evaluation of the BAR criteria in 22 subjects indicated conversion rates to proxies of first-episode mania of 23% within 265 days on average, and high specificity and sensitivity of the criteria. If prospective studies confirm the validity of the BAR criteria, then the criteria would have the potential to open up new avenues of research for indicated prevention in BD and might therefore offer opportunities to ameliorate the severity of, or even prevent BD.
Keywords: Bipolar disorder, at-risk criteria, prodrome, conversion, prediction, mania, depression, neuroprogression, psychosis, hallucinations
Current Pharmaceutical Design
Title: Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder
Volume: 18 Issue: 4
Author(s): A. Bechdolf, A. Ratheesh, S. J. Wood, T. Tecic, P. Conus, B. Nelson, S. M. Cotton, A. M. Chanen, G. P. Amminger, S. Ruhrmann, F. Schultze-Lutter, J. Klosterkotter, P. Fusar Poli, A. R. Yung, M. Berk and P. D. McGorry
Affiliation:
Keywords: Bipolar disorder, at-risk criteria, prodrome, conversion, prediction, mania, depression, neuroprogression, psychosis, hallucinations
Abstract: Bipolar affective disorder (BD) is a severe, recurrent and disabling disorder with devastating consequences for individuals, families and society. Although these hazards and costs provide a compelling rationale for development of early detection and early intervention strategies in BD, the development of at-risk criteria for first episode mania is still in an early stage of development. In this paper we review the literature with respect to the clinical, neuroantomical and neuropsychological data, which support this goal. We also describe our recently developed bipolar at-risk criteria (BAR). This criteria comprises the peak age range of the first onset of bipolar disorder, genetic risk, presenting with sub-threshold mania, cyclothymic features or depressive symptoms. An initial pilot evaluation of the BAR criteria in 22 subjects indicated conversion rates to proxies of first-episode mania of 23% within 265 days on average, and high specificity and sensitivity of the criteria. If prospective studies confirm the validity of the BAR criteria, then the criteria would have the potential to open up new avenues of research for indicated prevention in BD and might therefore offer opportunities to ameliorate the severity of, or even prevent BD.
Export Options
About this article
Cite this article as:
Bechdolf A., Ratheesh A., J. Wood S., Tecic T., Conus P., Nelson B., M. Cotton S., M. Chanen A., P. Amminger G., Ruhrmann S., Schultze-Lutter F., Klosterkotter J., Fusar Poli P., R. Yung A., Berk M. and D. McGorry P., Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316226
DOI https://dx.doi.org/10.2174/138161212799316226 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluating Protein-protein Interaction (PPI) Networks for Diseases Pathway, Target Discovery, and Drug-design Using `In silico Pharmacology`
Current Protein & Peptide Science Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets Editorial (Hot Topic: Modifying Cardiovascular Risk Factors: New Markers of Cardiovascular Damage)
Current Pharmaceutical Design Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots
Current Vascular Pharmacology Development of Novel Cardiovascular Therapeutics From Small Regulatory RNA Molecules - An Outline of Key Requirements
Current Pharmaceutical Design Mechanisms Explaining the Influence of Subclinical Hypothyroidism on the Onset and Progression of Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Antioxidant Molecular Therapies for Oxidative Stress-Related Ailments
Current Gene Therapy Biomarkers in Acute Heart Failure Syndromes: An Update
Current Cardiology Reviews TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets
Current Alzheimer Research Non-Systemic Drugs: A Critical Review
Current Pharmaceutical Design Statins Attenuate Fibrotic Manifestations of Cardiac Tissue Damage
Current Molecular Pharmacology The Emerging Role of Coenzyme Q-10 in Aging, Neurodegeneration, Cardiovascular Disease, Cancer and Diabetes Mellitus
Current Neurovascular Research Consequences of Elevated Homocysteine During Embryonic Development and Possible Modes of Action
Current Pharmaceutical Design Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels
Current Neuropharmacology Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Current Drug Targets Obesity and Arterial Compliance Alterations
Current Vascular Pharmacology How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?
Current Cardiology Reviews Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management
Current Vascular Pharmacology Hyperglycemia and Perioperative Glucose Management
Current Pharmaceutical Design